Mitchel Sayare
CIK 1201196 · Chairman of the Board · last filed 2026-05-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IMGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
910 CLOPPER ROAD, SUITE 201S
GAITHERSBURG, MD 20878
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALT | Director | 27,451 | $2.19 | $60.3K | $10.0K | 13 | 2026-05-01 |
| Altimmune, Inc. (PIP) Delisted | Director | 21,714 | — | — | $10.8K | 11 | 2016-11-23 |
| ImmunoGen, Inc. (IMGN) Delisted | Director | 383,136 | $31.23 | $11.97M | -$4.31M | 21 | 2011-08-01 |
Recent Filings · Page 3 of 5
45 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-08-01 | ImmunoGen, Inc. (IMGN) Delisted | Sell (S) | −10,000 | -$132.5K | EDGAR |
| 2011-07-19 | Altimmune, Inc. (PIP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-07-18 | ImmunoGen, Inc. (IMGN) Delisted | Sell (S) | −10,000 | -$150.2K | EDGAR |
| 2011-06-27 | ImmunoGen, Inc. (IMGN) Delisted | Sell (S) | −10,000 | -$117.0K | EDGAR |
| 2011-06-27 | Altimmune, Inc. (PIP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-06-13 | ImmunoGen, Inc. (IMGN) Delisted | Sell (S) | −10,000 | -$116.9K | EDGAR |
| 2011-05-31 | ImmunoGen, Inc. (IMGN) Delisted | Sell (S) | −10,000 | -$122.4K | EDGAR |
| 2011-05-16 | ImmunoGen, Inc. (IMGN) Delisted | Sell (S) | −10,000 | -$132.3K | EDGAR |
| 2011-05-02 | ImmunoGen, Inc. (IMGN) Delisted | Sell (S) | −20,000 | -$265.5K | EDGAR |
| 2011-04-18 | ImmunoGen, Inc. (IMGN) Delisted | Sell (S) | −20,000 | -$242.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.